EDOCH Alternating With DHAP for New Diagnosed Younger MCL

• Status: Unknown status
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to:

1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years);

2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance regimens.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital
• Treatments: BB 1101; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Doxorubicin; Etoposide; Etoposide phosphate; Liposomal doxorubicin; Prednisone; Rituximab; Thalidomide; Vincristine

Criteria

Inclusion Criteria:

• age≤65 years

• diagnosis with mantle cell lymphoma

• Ann Arbor stage II,III or IV

• ECOG≤1 or if ECOG≥2 but recover after pretreatment.

Exclusion Criteria:

• with centre neural system involvement

• serious complications such as uncontrolled diabetes, gastric ulcer or other serious angiocardiopathy determined by the physician

• HIV positive or active HBV infection or other uncontrolled systematic infection

• clinical central nervous dysfunction

• serious surgery within 30 days

• pregnancy or baby nursing period or un-contracepted child bearing period woman.